A Phase 3 trial of OMS721 in IgA nephropathy.

Trial Profile

A Phase 3 trial of OMS721 in IgA nephropathy.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs OMS 721 (Primary)
  • Indications IgA nephropathy
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 According to an Omeros Corporation media release, the meeting minutes with FDA state approval for OMS721 in IgA nephropathy can be obtained with a single successful Phase 3 trial with reduction in proteinuria as the primary efficacy endpoint.
    • 20 Oct 2017 Status changed from planning to recruiting, according to Omeros Corporation media release.
    • 15 Aug 2017 According to Omeros Corporation media release, company is working with US FDA to finalize the protocol for this trial and expect to initiate the enrollment by end of the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top